- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Stakeholders Urge Faster Generic Approval, Save Healthcare Dollars
Earlier this week, the FDA heard from various stakeholders and experts from the healthcare industry on how delays in the generic approval process impact healthcare costs.
Earlier this week, the FDA heard from various stakeholders and experts from the healthcare industry on how delays in the generic approval process impact healthcare costs. The meeting saw participation by members of the Generics Pharmaceutical Association, Specialty Pharma Association, Bulk Pharmaceutical Task Force, and Kaiser Permanente's Medical Group.
Participants urged the FDA to reduce the generic drug review period (currently at about 50 months), which they say could have saved the healthcare system over $3 billion over a year and a half. These delays reduce access for patients who then have to turn to more expensive brand-name drugs.
Generic Drug User Fee Amendments (GDUFA) fee schedule; smaller companies or biotechs that file for an abbreviated new drug application have to pay the same GDUFA fees as big pharma, which
Perry Cole, president and executive director of Specialty Pharma Association, thinks “Is financially unfair to smaller companies.”
Another point raised during the meeting was the similar
Read more at Insider Health Policy: http://bit.ly/1JZKnBF
How FcRn Blockade Targets Myasthenia Gravis Autoantibodies
January 29th 2025In part 2 of our interview with Katie Abouzahr, MD, Johnson & Johnson Innovative Medicine, we discuss the challenge inherent in treating adolescents who have the myasthenia gravis and how nipocalimab works via FcRn blockade to reduce the circulating autoantibodies that drive myasthenia gravis.
Read More
